OR WAIT null SECS
August 29, 2023
Danaher intends to acquire Abcam, a provider of life sciences assays and reagents, for $5.7 billion.
August 24, 2023
The patent grants Alterity 20 years of exclusivity over a new class of iron chaperone drug candidates.
Royalty Pharma agreed to spend up to $500 million for a 5.1 to 8% royalty on net sales of Ferring’s gene therapy adstiladrin (nadofaragene firadenovec-vcng).
Bright Path will develop and produce APIs for hospitals facing drug shortages in the Capstone Health Alliance.
The formulation will be used to mitigate emerging infectious diseases and public health emergencies.
August 23, 2023
WuXi XDC will provide end-to-end services to support Boostimmune’s discovery of novel bioconjugates.
FDA has approved a new mAb therapy from Regeneron Pharmaceuticals as well as a higher dose version of Eylea, the company’s eye disease therapeutic.
The immunization, meant to protect infants aged six months or lower, is given to pregnant individuals at a gestation period of 32 to 36 weeks.
August 22, 2023
Ipsen’s Sohonos (palovarotene) capsules are designed to reduce new, abnormal bone formation in soft and connective tissues in individuals with fibrodysplasia ossificans progressiva, a rare bone disease.
Sartorius’ Biostat STR now incorporates Repligen’s XCell ATF hardware.